InfuSystem Holdings, Inc.

AMEX:INFU

Medical - Instruments & Supplies

Healthcare
$14.06 +4.00%

+$0.35 today

Market cap
$281.67M
Beta
1.42
P/E (TTM)
23.2
EPS (TTM)
$0.39
52W Low $5.38High $11.04

Volume 0.19M

Average 0.16M

Big Five Numbers

InfuSystem Holdings, Inc. growth analysis

Start with the long-run numbers that show whether INFU compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
Not availableNot available+629.0%+181.8%
Revenue
Not availableNot available+9.3%+6.4%
Equity
Not availableNot available+6.1%+2.6%
Cash
Not availableNot available+168.3%+504.6%
ROIC
Not available3.8%5.1%9.3%

Analysis

In the latest year, Cash was strongest at +504.6%, while Equity was weakest at +2.6%. The three-year average ROIC was 5.1%, a measure of how efficiently the company earned that growth.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/A+629.0%
+28.6% (3yr)1 analysts
RevenueN/AN/A+9.3%
+4.1% (3yr)2 analysts
Net IncomeN/AN/A+616.7%
+28.2% (3yr)2 analysts
EBITN/AN/A+93.2%
+17.7% (3yr)2 analysts

Analysis

Recent growth has been strongest in EPS at +629.0% over three years. Forward estimates point to EPS at +28.6% (3yr), giving you a quick check on whether expectations are accelerating or cooling.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where INFU earns its revenue, as reported in company filings

  • Patient Services
  • Device Solutions
  • ITS
  • Third-Party Payer Rental
  • DME Services
  • Service
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
Patient Services$86.53M57.4%+7.7%
Device Solutions$64.1M42.6%+3.8%

Figures in USD. Segments account for 105.0% of reported FY2025 revenue; -$7.19M is not attributed to a segment.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income$6.6M
+ D&A$13.3M
+ Stock-Based Comp$4.4M
+ Deferred Tax$2.7M
- Working Capital-$94.0K
- Other Non-Cash-$2.5M
= Operating Cash Flow$24.4M
- Capex-$560.0K
= Free Cash Flow$23.8M

Analysis

FY2025 free cash flow is $23.8M. FCF conversion is 359.9% of net income. Operating cash flow was $24.4M, with capex of -$560.0K. The largest bridge item is D&A at $13.3M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for INFU.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for INFU.

Sign in free

Competitor growth

How does InfuSystem Holdings, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

ICU Medical, Inc.

ICUI

$4.48B+20.6%+11.9%-0.7%
+1.2% (5yr)3 analysts

KORU Medical Systems, Inc.

KRMD

$160.49M+12.9%+11.2%+13.8%
+16.4% (3yr)2 analysts

Questions

Growth questions

Common questions about INFU's growth, answered from reported and forecast figures.

Is INFU growing revenue?

Revenue grew 6.4% year over year, from $134.86M to $143.44M.

Is INFU turning growth into profit?

The latest net margin is 4.6%, which shows how much revenue became net income.